BioSpace News Archive

Canadian health science companies define a new generation of innovation on the world stage

The Supervisory Board of Sartorius AG approved the Executive Board’s recommendation to submit a proposal to the Annual General Shareholders’ Meeting on March 26, 2020, to pay dividends of 0.71 euro per preference share and 0.70 euro per ordinary share.

Feb. 13, 2020 16:10 UTC More than 20,000 attendees networked around the latest in biomedical imaging, laser technology, and AR/VR/MR at the largest annual global optics and photonics event BELLINGHAM, Wash.--( BUSINESS WIRE )-- At the world’s largest photonics conference, more than 20,000 attendees packed San Francisco’s Moscone Center from 1 February through 6 February. Across one vibrant week, the SPIE Photonics West symposium , its BiOS, LASE, and OPTO symposia, and the i

LAS VEGAS, Feb. 13, 2020 (GLOBE NEWSWIRE) -- Zhittya Genesis Medicine, Inc. (a private company) (“Zhittya” or the “Company”), announced that it has received official regulatory approval from COFEPRIS, the Mexican governing body which would be the country’s equivalent of the U.S. Food and Drug Administration (FDA), to test its novel biological drug in subjects with Parkinson’s disease. The Phase I clinical study will be conducted at the Zambrano Hospital in Monterrey, Mexico, a new, state

New Data Presented at ASCO Genitourinary Cancers Symposium Finds Adding PROVENGE to Commonly Prescribed Oral Therapies Extends Median Survival by 14.5 Months

In the wake of the Trump Administration’s new regulations for organ procurement organizations, Dallas-based Southwest Transplant Alliance is ready to meet and exceed Washington’s expectations.

Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report its audited 2019 fourth quarter and full-year financial results and provide a corporate update on February 20, 2020.

Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020.

Shockwave Medical, Inc. (Nasdaq: SWAV), a pioneer in the development and commercialization of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, today reported financial results for the three months and full year ended December 31, 2019.

Collegium Announces Closing of Convertible Senior Notes Offering and Exercise in Full of Over-Allotment Option